GlassScriptPhysician profile
Mtanius A Sultani
NPI 1972577930
$3,158.83
in general payments reported to CMS, 2019-2025
35 companies · $815 in 2025
The $815 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $91.25 · 2021: $246 · 2022: $483 · 2023: $438 · 2024: $768 · 2025: $815.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,021.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,020.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $340.99 | 2021-2025 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $325.86 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $298.44 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Amgen INC. | $225.59 | 2019-2023 | Lumakras |
| E.R. Squibb & Sons, L.L.C. | $209.68 | 2022-2025 | Opdualag, Opdivo |
| Lilly USA, LLC | $189.67 | 2022-2025 | Verzenio, Jaypirca |
| Exelixis INC. | $158.63 | 2022-2025 | Cabometyx |
| Pfizer INC. | $157.87 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $109.82 | 2019-2025 | Imfinzi, Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $101.73 | 2022-2025 | Ninlaro, Fruzaqla |
| Astellas Pharma US INC | $94.49 | 2023-2025 | Xtandi, Xospata, Vyloy |
| Teva Pharmaceuticals USA, INC. | $93.09 | 2019 | |
| Abbvie INC. | $86.56 | 2021-2024 | Venclexta |
| Eisai INC. | $84.67 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $64.01 | 2019-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $63.76 | 2024-2025 | Enhertu |
| Puma Biotechnology, INC. | $57.87 | 2021-2024 | |
| Janssen Biotech, INC. | $39.84 | 2024 | Tecvayli, Talvey, Darzalex |
| Incyte Corporation | $38.89 | 2024-2025 | Monjuvi, Jakafi |
| Celgene Corporation | $37.67 | 2024-2025 | Reblozyl |
| Genzyme Corporation | $36.60 | 2022 | |
| Janssen Pharmaceuticals, INC | $36.33 | 2021-2023 | Xarelto |
| Genmab U.S., INC. | $36.10 | 2023-2024 | Epkinly |
| Emd Serono, INC. | $33.74 | 2022-2023 | Bavencio |
| Glaxosmithkline, LLC. | $32.90 | 2023-2024 | Ojjaara |
| Stemline Therapeutics INC. | $31.57 | 2023-2025 | Orserdu |
| Pharmacyclics LLC, An Abbvie Company | $30.64 | 2023 | Imbruvica |
| Mirati Therapeutics, INC. | $26.13 | 2023 | Krazati |
| Myriad Genetic Laboratories, INC. | $25.59 | 2025 | Myrisk |
| Aveo Pharmaceuticals, INC. | $17.86 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $17.78 | 2025 | Libtayo |
| Seagen INC. | $15.51 | 2021 | |
| Novocure INC. | $14.55 | 2025 | Optune Lua (Novottf-200t) |
| Tersera Therapeutics LLC | $12.29 | 2019 | |
| Collegium Pharmaceutical, INC. | $12.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mtanius Sultani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.